diffuse large B-cell lymphoma (Cancer)
Information
- Disease name
- diffuse large B-cell lymphoma
- Disease ID
- DOID:0050745
- Description
- "A large B-cell lymphoma that is consisting of medium-sized to large B cells with a diffuse growth pattern." [url:http\://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma, url:https\://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148392, url:https\://www.ncbi.nlm.nih.gov/pubmed/28487884]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05179603 | Active, not recruiting | Phase 2 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | December 7, 2021 | January 14, 2025 |
| NCT04824092 | Active, not recruiting | Phase 3 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | May 11, 2021 | May 2026 |
| NCT04231448 | Active, not recruiting | Phase 3 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL | May 21, 2020 | March 1, 2025 |
| NCT03530683 | Active, not recruiting | Phase 1 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | June 7, 2018 | September 11, 2024 |
| NCT02329080 | Active, not recruiting | Phase 2 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | December 2014 | December 2023 |
| NCT04404283 | Active, not recruiting | Phase 3 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | August 20, 2020 | April 30, 2027 |
| NCT04182204 | Active, not recruiting | Phase 3 | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | February 7, 2020 | March 30, 2025 |
| NCT01793233 | Active, not recruiting | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | June 17, 2013 | December 31, 2024 | |
| NCT02900651 | Active, not recruiting | Phase 1 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | October 3, 2016 | July 26, 2024 |
| NCT03984448 | Active, not recruiting | Phase 2/Phase 3 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | October 22, 2019 | April 1, 2028 |
| NCT03955783 | Active, not recruiting | Phase 1 | Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies | June 21, 2019 | December 1, 2024 |
| NCT03939182 | Active, not recruiting | Phase 1 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | May 29, 2019 | May 2025 |
| NCT02734771 | Active, not recruiting | Phase 2 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | June 2016 | June 2024 |
| NCT03274492 | Active, not recruiting | Phase 3 | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | November 16, 2017 | June 27, 2024 |
| NCT02752815 | Active, not recruiting | Phase 4 | Reduced Chemotherapy in Low Risk DLBCL | June 14, 2016 | December 31, 2024 |
| NCT02481310 | Active, not recruiting | Phase 1/Phase 2 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | October 28, 2015 | July 2024 |
| NCT02763319 | Active, not recruiting | Phase 2/Phase 3 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | June 2016 | June 2024 |
| NCT04696692 | Active, not recruiting | N/A | Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma | February 9, 2021 | October 2025 |
| NCT04517435 | Active, not recruiting | Phase 1/Phase 2 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | April 28, 2021 | July 2025 |
| NCT03884998 | Active, not recruiting | Phase 1 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | February 26, 2019 | July 16, 2024 |
| NCT04433182 | Active, not recruiting | Phase 2 | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma | August 18, 2020 | August 1, 2024 |
| NCT03749018 | Active, not recruiting | Phase 2 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | January 2, 2019 | July 31, 2024 |
| NCT03677154 | Active, not recruiting | Phase 1/Phase 2 | Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma | May 23, 2019 | August 3, 2025 |
| NCT04628494 | Active, not recruiting | Phase 3 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL | January 13, 2021 | April 2028 |
| NCT03213977 | Active, not recruiting | Phase 3 | R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL | July 10, 2017 | July 13, 2024 |
| NCT04529772 | Active, not recruiting | Phase 3 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | October 8, 2020 | February 5, 2027 |
| NCT05108805 | Active, not recruiting | N/A | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | December 2, 2021 | December 31, 2024 |
| NCT01483664 | Active, not recruiting | Communication Skills Intervention to Promote Transition Into Survivorship | November 2011 | November 2024 | |
| NCT04323956 | Active, not recruiting | Phase 1 | Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | June 15, 2020 | May 15, 2027 |
| NCT01030900 | Completed | Phase 2 | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | October 22, 2009 | August 6, 2021 |
| NCT01040871 | Completed | Phase 2 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | January 2010 | August 2012 |
| NCT01087424 | Completed | Phase 2 | Mini-CHOP and Rituximab in Patients Aged Over 80 Years | April 2006 | June 2010 |
| NCT01122472 | Completed | Phase 3 | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP | April 2009 | September 2019 |
| NCT04726995 | Completed | DLBCL Treatment in Children and Adolescents | January 1, 2000 | October 1, 2020 | |
| NCT01177397 | Completed | Phase 1/Phase 2 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | July 20, 2010 | December 9, 2016 |
| NCT01186978 | Completed | N/A | Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma | September 20, 2010 | June 4, 2019 |
| NCT01197560 | Completed | Phase 2/Phase 3 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | September 2, 2010 | April 5, 2018 |
| NCT01202448 | Completed | N/A | Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma | August 2010 | February 2015 |
| NCT01226849 | Completed | Phase 1 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma | November 2010 | November 2014 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01234467 | Completed | Phase 2 | Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | March 2011 | August 2016 |
| NCT01321541 | Completed | Phase 3 | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant | April 20, 2011 | September 14, 2018 |
| NCT01340443 | Completed | An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | January 19, 2011 | July 15, 2016 | |
| NCT01361191 | Completed | Phase 2 | Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | June 2007 | September 2012 |
| NCT01369784 | Completed | Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma | February 2009 | March 2011 | |
| NCT01397825 | Completed | Phase 1/Phase 2 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | August 9, 2011 | October 5, 2016 |
| NCT01453205 | Completed | Phase 2 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | February 27, 2012 | July 11, 2016 |
| NCT01470456 | Completed | Phase 2 | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | November 2011 | September 2014 |
| NCT01472887 | Completed | Phase 2 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients | January 2012 | September 2016 |
| NCT01499303 | Completed | Phase 2 | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | December 2011 | October 2013 |
| NCT01502982 | Completed | Phase 2 | Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) | November 2004 | May 2014 |
| NCT01523834 | Completed | Phase 2 | Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT | February 2011 | April 2017 |
| NCT01562977 | Completed | Phase 2 | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL | April 2011 | April 2015 |
| NCT01562990 | Completed | Phase 1/Phase 2 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | December 2012 | March 2016 |
| NCT01606605 | Completed | Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma | January 2011 | December 2012 | |
| NCT01622439 | Completed | Phase 1/Phase 2 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma | June 2012 | March 2018 |
| NCT01626352 | Completed | Phase 2 | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy | October 2012 | April 2017 |
| NCT04361279 | Completed | Phase 3 | A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | July 25, 2019 | May 20, 2022 |
| NCT01660776 | Completed | BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology | June 7, 2012 | October 2, 2019 | |
| NCT01691898 | Completed | Phase 1/Phase 2 | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | September 27, 2012 | February 7, 2019 |
| NCT01713582 | Completed | Phase 1 | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | December 14, 2012 | January 20, 2017 |
| NCT01741792 | Completed | Phase 2 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | July 2012 | September 2015 |
| NCT04134936 | Completed | Phase 1 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | December 11, 2019 | August 10, 2022 |
| NCT01842672 | Completed | Phase 1/Phase 2 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia | March 2013 | September 2022 |
| NCT01846390 | Completed | Phase 1 | Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | October 1, 2013 | September 19, 2018 |
| NCT01851551 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | September 2001 | April 2005 |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT01953692 | Completed | Phase 1 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | November 22, 2013 | June 26, 2020 |
| NCT03677128 | Completed | N/A | Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment | July 23, 2019 | April 22, 2022 |
| NCT03664336 | Completed | Refractory Diffuse Large B-cell Lymphoma | November 2016 | January 2018 | |
| NCT02060435 | Completed | Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma | January 2013 | February 2014 | |
| NCT03630159 | Completed | Phase 1 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients | October 9, 2018 | July 20, 2021 |
| NCT02142530 | Completed | Phase 1 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | October 2014 | January 2018 |
| NCT03538028 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | June 18, 2018 | October 7, 2020 |
| NCT02268045 | Completed | Phase 3 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | May 2013 | July 2017 |
| NCT02340936 | Completed | Phase 1/Phase 2 | Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | January 2011 | February 20, 2019 |
| NCT03520920 | Completed | Phase 2 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | January 4, 2018 | August 28, 2020 |
| NCT02399085 | Completed | Phase 2 | Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL | March 29, 2016 | April 19, 2023 |
| NCT02401048 | Completed | Phase 1/Phase 2 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | May 2015 | November 2017 |
| NCT02412267 | Completed | Phase 2 | Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) | April 2011 | March 2016 |
| NCT03485118 | Completed | Phase 2 | RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | May 12, 2016 | January 14, 2018 |
| NCT02431988 | Completed | Phase 1 | Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation | June 2016 | March 21, 2022 |
| NCT02471911 | Completed | Phase 1 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | December 11, 2015 | October 14, 2021 |
| NCT03263026 | Completed | Phase 3 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | March 20, 2018 | July 12, 2022 |
| NCT03255096 | Completed | Phase 1 | A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 | August 28, 2017 | July 3, 2019 |
| NCT02890602 | Completed | Phase 2 | Erythropoietin for Management of Anemia Caused by Chemotherapy | September 1, 2012 | December 7, 2017 |
| NCT02549651 | Completed | Phase 1 | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | July 13, 2016 | February 4, 2019 |
| NCT02564744 | Completed | Phase 2 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | June 5, 2016 | June 25, 2021 |
| NCT02617485 | Completed | Phase 3 | MabionCD20 Compared to MabThera in Lymphoma Patients | December 2015 | January 2018 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT02660710 | Completed | Phase 2 | Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma | March 2016 | July 22, 2022 |
| NCT03145064 | Completed | Phase 2 | Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma | June 30, 2017 | September 3, 2020 |
| NCT03128359 | Completed | Phase 2 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | May 30, 2017 | September 15, 2021 |
| NCT02708732 | Completed | Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) | May 31, 2016 | October 31, 2016 | |
| NCT03106428 | Completed | Phase 1 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | March 29, 2017 | January 3, 2020 |
| NCT03255018 | Completed | Phase 2 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | February 15, 2018 | June 29, 2023 |
| NCT00075478 | Completed | Phase 3 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | October 2003 | February 2, 2014 |
| NCT00355199 | Completed | Phase 3 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | May 2005 | March 2013 |
| NCT06392763 | Completed | Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data | August 3, 2021 | April 28, 2023 | |
| NCT00440583 | Completed | Phase 2 | The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP | September 2006 | May 2012 |
| NCT06271369 | Completed | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. | August 11, 2022 | February 15, 2023 | |
| NCT05918809 | Completed | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings | July 25, 2021 | June 17, 2022 | |
| NCT00553943 | Completed | Phase 2 | Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis | July 2007 | March 2017 |
| NCT00556127 | Completed | Phase 2 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | June 2002 | September 2006 |
| NCT00575406 | Completed | Phase 2 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | December 2007 | January 2012 |
| NCT00607854 | Completed | Phase 2 | Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) | February 2008 | November 2011 |
| NCT00644189 | Completed | Phase 1/Phase 2 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | June 2008 | July 2021 |
| NCT00697346 | Completed | Phase 1 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | July 11, 2008 | October 19, 2016 |
| NCT00754117 | Completed | Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) | May 2008 | December 8, 2012 | |
| NCT00789776 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | October 13, 2008 | May 2017 |
| NCT00790036 | Completed | Phase 3 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | July 24, 2009 | June 15, 2016 |
| NCT00794638 | Completed | Phase 1 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | November 2008 | May 2010 |
| NCT00799513 | Completed | Phase 2 | Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma | March 2009 | August 2021 |
| NCT00807495 | Completed | Phase 2 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | February 10, 2009 | February 13, 2013 |
| NCT00831597 | Completed | Phase 2 | Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | November 2008 | September 2013 |
| NCT05541328 | Completed | Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel | February 3, 2020 | February 5, 2021 | |
| NCT00842595 | Completed | Phase 2 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | December 2003 | May 2010 |
| NCT05338892 | Completed | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | June 22, 2022 | October 5, 2023 | |
| NCT00850512 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy | ||
| NCT00869999 | Completed | Phase 2 | Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | May 2009 | November 2011 |
| NCT05144009 | Completed | Phase 2 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | June 21, 2022 | January 22, 2024 |
| NCT05113576 | Completed | Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL | October 10, 2013 | June 30, 2021 | |
| NCT00968656 | Completed | Phase 1 | Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1 | January 2009 | November 2011 |
| NCT04833504 | Completed | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | July 1, 2018 | October 1, 2020 | |
| NCT02752204 | Completed | Phase 2 | An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma | October 2015 | February 6, 2020 |
| NCT03036904 | Completed | Phase 1 | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | February 6, 2017 | November 11, 2021 |
| NCT01804686 | Enrolling by invitation | Phase 3 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | September 9, 2013 | January 29, 2027 |
| NCT05690191 | Enrolling by invitation | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | June 1, 2021 | August 1, 2026 | |
| NCT03399747 | Enrolling by invitation | Phase 2 | Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma | December 7, 2016 | December 31, 2024 |
| NCT04381741 | Enrolling by invitation | Phase 1 | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma | June 18, 2020 | September 1, 2023 |
| NCT06441097 | Not yet recruiting | Phase 2 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | December 31, 2024 | December 31, 2027 |
| NCT05280626 | Not yet recruiting | Phase 2 | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP | March 25, 2022 | December 31, 2026 |
| NCT05575973 | Not yet recruiting | Phase 2 | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | October 10, 2022 | October 2025 |
| NCT05777369 | Not yet recruiting | N/A | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | March 2023 | August 2024 |
| NCT05784987 | Not yet recruiting | N/A | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | April 15, 2023 | January 1, 2025 |
| NCT05883709 | Not yet recruiting | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | July 1, 2023 | December 30, 2024 | |
| NCT05952024 | Not yet recruiting | Phase 2 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | March 29, 2024 | September 29, 2027 |
| NCT05990985 | Not yet recruiting | N/A | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | September 1, 2023 | August 1, 2026 |
| NCT06224309 | Not yet recruiting | Preliminary Assessment of [18F]BL40 in PET/CT Scans | May 2024 | October 2025 | |
| NCT06249191 | Not yet recruiting | Phase 1/Phase 2 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | May 31, 2024 | April 1, 2027 |
| NCT06395103 | Not yet recruiting | Phase 1/Phase 2 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | June 4, 2024 | March 31, 2029 |
| NCT05715606 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | February 10, 2023 | May 15, 2025 |
| NCT05896163 | Recruiting | Phase 1/Phase 2 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. | August 30, 2023 | June 19, 2028 |
| NCT04604067 | Recruiting | Phase 2 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | June 25, 2021 | December 2030 |
| NCT05455697 | Recruiting | Phase 1/Phase 2 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | January 26, 2023 | July 6, 2026 |
| NCT05451810 | Recruiting | Phase 2 | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | August 17, 2022 | May 1, 2029 |
| NCT04661007 | Recruiting | Phase 1/Phase 2 | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | December 15, 2020 | July 20, 2026 |
| NCT05444322 | Recruiting | Early Phase 1 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | July 5, 2022 | July 10, 2025 |
| NCT04663347 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | November 3, 2020 | March 31, 2029 |
| NCT05432635 | Recruiting | Phase 1 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | August 1, 2023 | December 30, 2028 |
| NCT05660967 | Recruiting | Phase 2 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | March 6, 2023 | March 2027 |
| NCT04739813 | Recruiting | Phase 1 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | July 9, 2021 | July 15, 2029 |
| NCT05429268 | Recruiting | Phase 3 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | December 23, 2022 | December 24, 2026 |
| NCT06031194 | Recruiting | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma | May 10, 2023 | December 31, 2024 | |
| NCT05265975 | Recruiting | Phase 1/Phase 2 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL | April 7, 2022 | June 7, 2025 |
| NCT04844866 | Recruiting | Phase 2 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | August 18, 2021 | July 31, 2027 |
| NCT04850495 | Recruiting | Phase 1 | Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | November 16, 2021 | December 31, 2024 |
| NCT05257018 | Recruiting | Phase 2 | R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse | February 26, 2022 | January 30, 2028 |
| NCT05256641 | Recruiting | Phase 1/Phase 2 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | January 23, 2023 | October 1, 2025 |
| NCT04978584 | Recruiting | Phase 2 | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | March 3, 2022 | January 16, 2025 |
| NCT04981795 | Recruiting | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | September 20, 2021 | August 31, 2026 | |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT05097443 | Recruiting | Phase 3 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | April 15, 2021 | December 31, 2024 |
| NCT05875428 | Recruiting | Phase 2 | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | July 10, 2023 | September 30, 2025 |
| NCT03147885 | Recruiting | Phase 1/Phase 2 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | June 20, 2017 | December 2026 |
| NCT05121103 | Recruiting | Phase 1 | A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma | November 11, 2021 | June 27, 2025 |
| NCT05139017 | Recruiting | Phase 2/Phase 3 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | January 14, 2022 | June 21, 2027 |
| NCT05660395 | Recruiting | Phase 1 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | August 28, 2023 | April 5, 2027 |
| NCT05659628 | Recruiting | Phase 1 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | December 2022 | December 2026 |
| NCT05179733 | Recruiting | Phase 3 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | March 2, 2022 | December 25, 2025 |
| NCT05192486 | Recruiting | Phase 1/Phase 2 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | August 10, 2022 | August 2024 |
| NCT06290817 | Recruiting | Phase 2 | Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI | March 30, 2023 | March 20, 2026 |
| NCT05658562 | Recruiting | Phase 1/Phase 2 | A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL | January 30, 2023 | August 2028 |
| NCT02449278 | Recruiting | Phase 3 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | October 2015 | October 2025 |
| NCT05633615 | Recruiting | Phase 2 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | June 12, 2023 | December 4, 2029 |
| NCT05823701 | Recruiting | Phase 2 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | September 30, 2022 | December 31, 2025 |
| NCT02449265 | Recruiting | Phase 3 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | October 2015 | October 2025 |
| NCT05626322 | Recruiting | Phase 2 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | August 4, 2023 | February 8, 2029 |
| NCT05618028 | Recruiting | Phase 1 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | April 4, 2023 | June 27, 2027 |
| NCT05954910 | Recruiting | A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma | August 25, 2023 | September 30, 2026 | |
| NCT03960840 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL | June 26, 2019 | June 30, 2027 |
| NCT03501576 | Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma | April 6, 2018 | October 22, 2024 | |
| NCT04002947 | Recruiting | Phase 2 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | August 5, 2019 | March 31, 2029 |
| NCT05578976 | Recruiting | Phase 3 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | February 8, 2023 | December 30, 2029 |
| NCT06120166 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | November 20, 2023 | April 5, 2026 |
| NCT04094311 | Recruiting | Phase 3 | Study of Out of Specification for Tisagenlecleucel | November 21, 2019 | April 18, 2025 |
| NCT05541341 | Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | November 24, 2023 | December 16, 2038 | |
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT02393157 | Recruiting | Phase 2 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | August 21, 2015 | December 2024 |
| NCT03223610 | Recruiting | Phase 1/Phase 2 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | February 9, 2018 | December 1, 2026 |
| NCT05518383 | Recruiting | Phase 4 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | May 25, 2022 | May 16, 2027 |
| NCT02227251 | Recruiting | Phase 2 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | November 2014 | November 2027 |
| NCT05512390 | Recruiting | Phase 1 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | April 26, 2023 | February 7, 2027 |
| NCT06244368 | Recruiting | Phase 2 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | January 17, 2024 | June 30, 2027 |
| NCT03656835 | Recruiting | N/A | Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma | September 26, 2018 | December 31, 2024 |
| NCT04408638 | Recruiting | Phase 3 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | February 23, 2021 | April 15, 2025 |
| NCT05498259 | Recruiting | Phase 2 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | July 27, 2022 | January 1, 2025 |
| NCT05498220 | Recruiting | Phase 2 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | February 17, 2023 | August 2028 |
| NCT04442412 | Recruiting | Phase 3 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy | March 23, 2021 | September 1, 2030 |
| NCT04479267 | Recruiting | Phase 2 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | August 21, 2020 | November 15, 2026 |
| NCT04512716 | Recruiting | Early Phase 1 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | February 2, 2021 | January 2025 |
| NCT03864419 | Terminated | Phase 1 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | October 24, 2019 | July 26, 2023 |
| NCT02702141 | Terminated | Phase 1 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | February 2016 | July 10, 2018 |
| NCT02700022 | Terminated | Phase 1 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | October 2016 | August 18, 2017 |
| NCT02531308 | Terminated | Phase 2 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | July 2015 | July 2016 |
| NCT02483000 | Terminated | Phase 1 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | February 1, 2017 | September 2, 2020 |
| NCT02420210 | Terminated | Phase 2 | Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma | November 2015 | August 2016 |
| NCT02323230 | Terminated | Phase 2 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL | January 2015 | February 2018 |
| NCT03670901 | Terminated | Phase 3 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) | November 13, 2018 | March 7, 2019 |
| NCT01944943 | Terminated | Phase 2 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia | February 2013 | October 2014 |
| NCT03684694 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | December 1, 2018 | November 8, 2022 |
| NCT03685344 | Terminated | Phase 1 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | February 4, 2019 | October 27, 2020 |
| NCT01914718 | Terminated | Phase 2 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | February 2013 | December 2017 |
| NCT03797261 | Terminated | Phase 1 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | March 18, 2019 | December 30, 2019 |
| NCT03123393 | Terminated | Phase 2 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | October 10, 2017 | December 17, 2019 |
| NCT03876028 | Terminated | Phase 1 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | June 11, 2019 | November 1, 2021 |
| NCT01799889 | Terminated | Phase 2 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | March 14, 2013 | January 30, 2020 |
| NCT01796470 | Terminated | Phase 2 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | June 20, 2013 | December 22, 2016 |
| NCT01724294 | Terminated | An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma | December 2012 | April 2016 | |
| NCT04254107 | Terminated | Phase 1 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | May 29, 2020 | December 1, 2023 |
| NCT04358458 | Terminated | Phase 1/Phase 2 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | March 24, 2020 | July 28, 2023 |
| NCT01534949 | Terminated | Phase 1 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial | February 2012 | February 2013 |
| NCT01510184 | Terminated | Phase 3 | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy | April 19, 2012 | October 23, 2014 |
| NCT01402440 | Terminated | Phase 1 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | November 2011 | April 2014 |
| NCT01287741 | Terminated | Phase 3 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | July 26, 2011 | January 31, 2018 |
| NCT01144403 | Terminated | Phase 2 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | June 2010 | August 2014 |
| NCT05022797 | Terminated | Phase 2 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | July 19, 2021 | November 22, 2022 |
| NCT00978432 | Terminated | Phase 2 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | February 2012 | March 2016 |
| NCT00968331 | Terminated | Phase 2 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | March 2009 | December 2011 |
| NCT00918463 | Terminated | Phase 2 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | June 2009 | May 23, 2011 |
| NCT00902525 | Terminated | Phase 2 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | January 2008 | September 2011 |
| NCT00386321 | Terminated | Phase 2 | Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma | April 2006 | January 2010 |
| NCT00022971 | Terminated | Phase 1 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | August 15, 2001 | March 17, 2017 |
| NCT00474188 | Terminated | Phase 2 | A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | May 2007 | December 2008 |
| NCT02793583 | Terminated | Phase 2/Phase 3 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | May 25, 2016 | July 4, 2022 |
| NCT02815397 | Terminated | Phase 2 | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma | February 2016 | July 2016 |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT02951156 | Terminated | Phase 3 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | December 16, 2016 | December 2, 2019 |
| NCT01278602 | Unknown status | Phase 2 | R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | December 2010 | February 2014 |
| NCT01279902 | Unknown status | Phase 2 | Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL | August 2010 | January 2017 |
| NCT04610970 | Unknown status | Phase 2 | A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） | January 20, 2021 | June 30, 2022 |
| NCT03022123 | Unknown status | N/A | The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma | November 2016 | March 2018 |
| NCT02842931 | Unknown status | Phase 3 | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | February 2015 | February 2023 |
| NCT04914143 | Unknown status | N/A | the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy | June 6, 2020 | December 30, 2023 |
| NCT01009970 | Unknown status | Phase 2 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | May 2010 | May 2012 |
| NCT04827004 | Unknown status | Phase 2 | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | April 2021 | December 31, 2022 |
| NCT00846157 | Unknown status | Phase 3 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients | September 2007 | September 2014 |
| NCT04661943 | Unknown status | Phase 2 | Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma | November 30, 2020 | November 30, 2022 |
| NCT04425824 | Unknown status | Phase 2 | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma | June 15, 2020 | December 31, 2022 |
| NCT01653067 | Unknown status | Phase 2 | STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma | September 2012 | July 2018 |
| NCT01670370 | Unknown status | Phase 2 | Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | August 2012 | December 2019 |
| NCT01793844 | Unknown status | A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients | January 2008 | December 2017 | |
| NCT04026100 | Unknown status | Phase 1 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | December 1, 2019 | December 31, 2022 |
| NCT04023916 | Unknown status | Phase 2 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | December 1, 2019 | July 30, 2021 |
| NCT01804127 | Unknown status | Phase 2 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | February 2013 | December 2017 |
| NCT01852435 | Unknown status | Phase 3 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | May 2013 | February 2018 |
| NCT01865058 | Unknown status | The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma. | June 2011 | August 2014 | |
| NCT03777085 | Unknown status | Phase 3 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | January 10, 2019 | December 30, 2020 |
| NCT03742258 | Unknown status | Phase 1 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | March 13, 2019 | August 1, 2022 |
| NCT03720457 | Unknown status | Phase 1 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | November 13, 2018 | October 2023 |
| NCT01990144 | Unknown status | Phase 2 | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL | November 2011 | February 2016 |
| NCT02753647 | Unknown status | Phase 2 | Chidamide Plus R-CHOP in Elderly DLBCL | April 2016 | April 2019 |
| NCT02060656 | Unknown status | Phase 2 | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) | September 2013 | August 2023 |
| NCT02542111 | Unknown status | Phase 2 | A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL | May 2015 | May 2018 |
| NCT02792491 | Unknown status | Phase 2 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | August 2012 | December 2017 |
| NCT03229616 | Unknown status | Phase 2/Phase 3 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | July 5, 2017 | June 2020 |
| NCT00499018 | Unknown status | Phase 3 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | January 2006 | September 2013 |
| NCT02777736 | Unknown status | Phase 3 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma | July 2015 | December 2019 |
| NCT02692248 | Unknown status | Phase 2 | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation | April 7, 2016 | September 2020 |
| NCT03151044 | Unknown status | Phase 3 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | July 2016 | July 2017 |
| NCT02733380 | Unknown status | Phase 2 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | May 2016 | May 2021 |
| NCT01423539 | Withdrawn | Phase 2 | A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | October 2011 | February 2014 |
| NCT04974996 | Withdrawn | Phase 1 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | February 1, 2022 | May 5, 2027 |
| NCT01101581 | Withdrawn | Phase 1/Phase 2 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | May 2010 | March 2017 |
| NCT03349346 | Withdrawn | Phase 1 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | June 2019 | February 2026 |
| NCT00836173 | Withdrawn | Phase 2 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | July 2008 | May 2012 |
| NCT00776802 | Withdrawn | Phase 1/Phase 2 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | July 2008 | April 2009 |
| NCT02054559 | Withdrawn | Phase 3 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL | January 2020 |
- Disase is a (Disease Ontology)
- DOID:0081452
- Cross Reference ID (Disease Ontology)
- GARD:3178
- Cross Reference ID (Disease Ontology)
- ICD11:2A81.Z
- Cross Reference ID (Disease Ontology)
- ICDO:9680/3
- Cross Reference ID (Disease Ontology)
- MESH:D016403
- Cross Reference ID (Disease Ontology)
- NCI:C80280
- Exact Synonym (Disease Ontology)
- DLBCL
- OrphaNumber from OrphaNet (Orphanet)
- 544
- ICD10 preferred id (Insert disease from ICD10)
- D0002247
- ICD10 class code (Insert disease from ICD10)
- C83.3